Effects of stimulating interleukin -2/anti- interleukin -2 antibody complexes on renal cell carcinoma
Open Access
- 16 January 2016
- journal article
- research article
- Published by Springer Nature in BMC Urology
- Vol. 16 (1) , 1-11
Abstract
Current therapies for advanced renal cell carcinoma (RCC) have low cure rates or significant side effects. It has been reported that complexes composed of interleukin (IL)-2 and stimulating anti-IL-2 antibody (IL-2C) suppress malignant melanoma growth. We investigated whether it could have similar effects on RCC. A syngeneic RCC model was established by subcutaneously injecting RENCA cells into BALB/c mice, which were administered IL-2C or phosphate-buffered saline every other day for 4 weeks. RCC size was measured serially, and its weight was assessed 4 weeks after RENCA injection. Immune cell infiltration into RCC lesions and spleen was assessed by flow cytometry and immunohistochemistry. IL-2C treatment increased the numbers of CD8+ memory T and natural killer (NK) cells in healthy BALB/c mice (P < 0.01). In the spleen of RCC mice, IL-2C treatment also increased the number of CD8+ memory T, NK cells, and macrophages as compared to PBS-treated controls (P < 0.01). The number of interferon-γ- and IL-10-producing splenocytes increased and decreased, respectively after 4 weeks in the IL-2C-treated mice (P < 0.01). Tumor-infiltrating immune cells including CD4+ T, CD8+ T, NK cells as well as macrophages were increased in IL-2C-treated mice than controls (P < 0.05). Pulmonary edema, the most serious side effect of IL-2 therapy, was not exacerbated by IL-2C treatment. However, IL-2C had insignificant inhibitory effect on RCC growth (P = 0.1756). IL-2C enhanced immune response without significant side effects; however, this activity was not sufficient to inhibit RCC growth in a syngeneic, murine model.Keywords
Funding Information
- Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A111355)
- SNUH Research Fund (0320140430, 2014-1033)
This publication has 30 references indexed in Scilit:
- A Systematic Review of the Efficacy and Safety Experience Reported for Sorafenib in Advanced Renal Cell Carcinoma (RCC) in the Post-Approval SettingPLOS ONE, 2015
- The autophagy sensor ITPR1 protects renal carcinoma cells from NK-mediated killingAutophagy, 2015
- Chemotherapy in metastatic renal cell carcinoma today? A systematic reviewAnti-Cancer Drugs, 2013
- Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patientsOncoImmunology, 2013
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cellsProceedings of the National Academy of Sciences, 2010
- In Vivo Expansion of Activated Naive CD8+ T Cells and NK Cells Driven by Complexes of IL-2 and Anti-IL-2 Monoclonal Antibody As Novel Approach of Cancer ImmunotherapyThe Journal of Immunology, 2009
- Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and HypophysitisJournal of Immunotherapy, 2007
- Selective Stimulation of T Cell Subsets with Antibody-Cytokine Immune ComplexesScience, 2006
- Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinomaCancer, 2003